Is Vilin Bio Med overvalued or undervalued?

As of 22 September 2025, the valuation grade for Vilin Bio Med has moved from very expensive to expensive, indicating a slight improvement in perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 33.55, an EV to EBIT of 36.07, and a Price to Book Value of 1.45.
In comparison to peers, Sun Pharma has a PE Ratio of 34.24 and an EV to EBITDA of 23.18, while Cipla, considered attractive, has a PE Ratio of 23.1 and an EV to EBITDA of 16.26. Despite the recent stock performance showing a 45.43% return over the past year compared to a -2.28% return for the Sensex, the valuation metrics suggest that Vilin Bio Med remains overvalued in the current market context.